Mibg (I123) Jobenguaan Curium Netherlands

Iobenguane I-123, the active ingredient in Mibg (I123) Jobenguaan Curium Netherlands, is a radiopharmaceutical presented as an injection for intravenous use. It enables diagnostic imaging of cardiac sympathetic innervation and neuroendocrine tumors in adult patients.

GNH USA supplies Mibg (I123) Jobenguaan Curium Netherlands as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and imaging clinics worldwide.

Iobenguane I-123 is used in nuclear medicine imaging to assess sympathetic nerve activity in specific organ systems.

- Cardiac sympathetic innervation imaging: visualizes myocardial nerve distribution to aid heart‑failure and arrhythmia risk assessment. - Pheochromocytoma detection: identifies catecholamine‑producing adrenal tumors by highlighting norepinephrine transporter activity. - Paraganglioma imaging: assists in locating extra‑adrenal neuroendocrine tumors for staging and treatment planning.

Iobenguane I-123 is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain or erythema. - Nausea or mild vomiting. - Transient headache. - Mild hypertension or dizziness.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Significant arrhythmias or cardiac conduction disturbances. - Severe hypotension or shock. - Radiation‑induced tissue injury, including thyroid dysfunction. - Pulmonary embolism (rare).

Use of Iobenguane I-123 requires careful consideration of patient‑specific factors.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; consider discontinuing nursing during and after administration. - Renal impairment: monitor because excretion may be reduced. - Thyroid disease: assess risk of iodine uptake and possible dysfunction. - Radiation safety: follow ALARA principles to protect staff and other patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane I-123 may interact with other agents that affect catecholamine pathways or iodine handling.

Major Interactions (Avoid): - Sympathomimetic agents: may compete for the norepinephrine transporter and reduce tracer uptake. - Beta‑blockers: can suppress cardiac sympathetic activity, affecting image interpretation. - Iodine‑containing contrast media: excess iodine may interfere with imaging quality.

Moderate Interactions (Monitor Closely): - MAO inhibitors: may alter catecholamine metabolism, influencing tracer distribution. - Thyroid hormone replacement: could affect iodine metabolism; monitor thyroid function tests.